Pharmacokinetics and pharmacodynamics of 3 dosages of oestriol after continuous vaginal ring administration for 21 days in healthy, postmenopausal women
ConclusionAll formulations released sufficient amounts of oestriol to trigger the maximum local effect. However, there was no difference between formulations regarding surrogate parameters for clinical efficacy. A dose ‐dependency; however, was clearly demonstrated for FSH and LH. The product was well tolerated and safe. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 27, 2018 Category: Drugs & Pharmacology Authors: R.V. Oliveira Filho, N.J. Antunes, J.O. Ilha, R.A. Moreno, R. Wedemeyer, A. Warnke, G. De Nucci Tags: ORIGINAL ARTICLE Source Type: research

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug –drug interaction
We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan‐based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mech anisms and management. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Gr égoire Narjoux, Justine Clarenne, Brahim Azzouz, Pauline‐Saraï Zeller, Florian Slimano, Olivier Bouché Tags: CASE REPORT Source Type: research

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Isla S. Mackenzie, Thomas M. MacDonald Tags: EDITORIAL Source Type: research

Issue Information
No abstract is available for this article. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Issue highlights
British Journal of Clinical Pharmacology, Volume 84, Issue 12, Page 2685-2686, December 2018. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE HIGHLIGHTS Source Type: research

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug –drug interaction
We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan‐based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mech anisms and management. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Gr égoire Narjoux, Justine Clarenne, Brahim Azzouz, Pauline‐Saraï Zeller, Florian Slimano, Olivier Bouché Tags: CASE REPORT Source Type: research

Identifying poor adherence to antihypertensive medications in patients with resistant hypertension
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Authors: Isla S. Mackenzie, Thomas M. MacDonald Tags: EDITORIAL Source Type: research

Issue Information
No abstract is available for this article. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research

Issue highlights
British Journal of Clinical Pharmacology, Volume 84, Issue 12, Page 2685-2686, December 2018. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 26, 2018 Category: Drugs & Pharmacology Tags: ISSUE HIGHLIGHTS Source Type: research

The Developing Regorafenib Eye drops for neovascular Age ‐related Macular degeneration (DREAM) study: an open‐label phase II trial
ConclusionsThe programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaboratepost hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye). (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 25, 2018 Category: Drugs & Pharmacology Authors: Antonia M. Joussen, Sebastian Wolf, Peter K. Kaiser, David Boyer, Thomas Schmelter, Rupert Sandbrink, Oliver Zeitz, Gesa Deeg, Annett Richter, Torsten Zimmermann, Joachim Hoechel, Ulf Buetehorn, Walter Schmitt, Brigitte Stemper, Michael K. B Tags: ORIGINAL ARTICLE Source Type: research

Clinical and Translational Pharmacological Aspects of the Management of Fibrous Dysplasia of Bone
AbstractFibrous dysplasia (FD) is a genetic, non ‐inheritable rare bone disease caused by a post‐zygotic activating mutation of the alpha subunit of the stimulatory G‐protein (Gαs) causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/MAS and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological issue...
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: M. Rotman, N.A.T. Hamdy, N.M. Appelman ‐Dijkstra Tags: REVIEW ‐THEMED ISSUE Source Type: research

Pharmacogenetics of artemether ‐lumefantrine influence on nevirapine disposition: clinically significant drug‐drug interaction?
ConclusionsThis approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolisers when nevirapine is co ‐administered with artemether‐lumefantrine. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: Sa ’ad T. Abdullahi, Adeniyi Olagunju, Julius O. Soyinka, Rahman A. Bolarinwa, Olusola J. Olarewaju, Moji T. Bakare‐Odunola, Andrew Owen, Saye Khoo Tags: ORIGINAL ARTICLE Source Type: research

Clinical and Translational Pharmacological Aspects of the Management of Fibrous Dysplasia of Bone
AbstractFibrous dysplasia (FD) is a genetic, non ‐inheritable rare bone disease caused by a post‐zygotic activating mutation of the alpha subunit of the stimulatory G‐protein (Gαs) causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/MAS and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological issue...
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: M. Rotman, N.A.T. Hamdy, N.M. Appelman ‐Dijkstra Tags: REVIEW ‐THEMED ISSUE Source Type: research